New registry aims to unlock TAVR benefits in complex heart valve disease
NCT ID NCT06589063
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This registry is tracking 1,350 people with severe low flow, low gradient aortic stenosis who are getting a TAVR procedure. Researchers are collecting data on risks, complications, and survival for up to 5 years. The goal is to better understand who does well with this treatment and why.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Transcatheter aortic valve replacement (TAVR)
- What this could lead to
- If successful, this registry could clarify which patients with this specific type of aortic stenosis benefit most from TAVR, improving treatment decisions.
- What could go wrong
- This is an observational registry, not a controlled trial, so it cannot prove cause and effect. Results may be influenced by patient selection and real-world variability.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOW FLOW, LOW GRADIENT AORTIC STENOSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Salerno
RECRUITINGSalerno, 84131, Italy